Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143614 | 0.83 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL24253890 | 0.80 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL24253741 | 0.77 | TSHR (0.39) | HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL24253736 | 0.76 | HSP90AB1 (0.41) | HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL19711969 | 0.76 | — | — | |
| SCHEMBL3188969 | 0.75 | HSD17B10 (0.55) | HSP90AA1HSP90AB1KDM4EHSD17B10 | |
| SCHEMBL29546940 | 0.75 | NPC1 (0.37) | HSP90AA1HSP90AB1HSD17B10NPC1 | |
| SCHEMBL95816 | 0.72 | — | — | |
| SCHEMBL24253744 | 0.72 | — | — | |
| SCHEMBL29287591 | 0.71 | KDM4E (0.48) | HSP90AA1HSP90AB1KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | HSP90AA1 2357/4885HSP90AB1 2143/4885KDM4E 2714/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | HSP90AA1 2357/4885HSP90AB1 2143/4885KDM4E 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.